Involvement of ribosomal protein L11 expression in sensitivity of gastric cancer against 5‑FU

Kawahata,Takuto; Kawahara,Kohichi; Shimokawa,Michiko; Sakiyama,Akie; Shiraishi,Takehiro; Minami,Kentaro; Yamamoto,Masatatsu; Shinsato,Yoshinari; Arima,Kazunari; Hamada,Toshiyuki; Furukawa,Tatsuhiko

doi:10.3892/ol.2020.11352

Involvement of ribosomal protein L11 expression in sensitivity of gastric cancer against 5‑FU

Authors:
- Takuto Kawahata
- Kohichi Kawahara
- Michiko Shimokawa
- Akie Sakiyama
- Takehiro Shiraishi
- Kentaro Minami
- Masatatsu Yamamoto
- Yoshinari Shinsato
- Kazunari Arima
- Toshiyuki Hamada
- Tatsuhiko Furukawa
View Affiliations

Affiliations: Department of Molecular Oncology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890‑8544, Japan, Department of Science and Engineering, Kagoshima University Graduate School of Science and Engineering, Kagoshima 890‑8580, Japan
Published online on: January 24, 2020 https://doi.org/10.3892/ol.2020.11352
Pages: 2258-2264
Copyright: © Kawahata et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

5‑Fluorouracil (5‑FU) is widely used in the treatment of various types of solid cancer. Our study showed that ribosomal protein L11 (RPL11) was a crucial factor affecting sensitivity of gastric cancer to 5‑FU, implying that RPL11 expression is a potential biomarker for predicting 5‑FU sensitivity. Kaplan‑Meier survival analysis indicated that high RPL11 expression in gastric cancer patients treated with 5‑FU was significantly associated with good prognosis. It was therefore investigated whether RPL11 affected the sensitivity of gastric cancer against 5‑FU using four human gastric cancer cell lines, MKN45 (wild‑type TP53 gene), NUGC4 (wild‑type), MKN7 (mutated), and KE39 cells (mutated). In vitro assays demonstrated that RPL11 knockdown in gastric cancer cell lines carrying the TP53 wild‑type gene attenuated 5‑FU‑induced cell growth suppression and activation of the P53 pathway, but not in cells carrying mutated TP53, suggesting that 5‑FU suppresses tumor progression via RPL11‑mediated activation of the P53 pathway in gastric cancer. The present study provides a potential therapeutic strategy for improving 5‑FU resistance in gastric cancer by elevating RPL11 expression.

View Figures

View References

1	Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
2	Houghton JA, Tillman DM and Harwood FG: Ratio of 2′-deoxyadenosine-5′-triphosphate/thymidine-5′-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin Cancer Res. 1:723–730. 1995.PubMed/NCBI
3	Sampath D, Rao VA and Plunkett W: Mechanisms of apoptosis induction by nucleoside analogs. Oncogene. 22:9063–9074. 2003. View Article : Google Scholar : PubMed/NCBI
4	Wilkinson DS and Pitot HC: Inhibition of ribosomal ribonucleic acid maturation in Novikoff hepatoma cells by 5-fluorouracil and 5-fluorouridine. J Biol Chem. 248:63–68. 1973.PubMed/NCBI
5	Kanamaru R, Kakuta H, Sato T, Ishioka C and Wakui A: The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro. Cancer Chemother Pharmacol. 17:43–46. 1986. View Article : Google Scholar : PubMed/NCBI
6	Ghoshal K and Jacob ST: Specific inhibition of pre-ribosomal RNA processing in extracts from the lymphosarcoma cells treated with 5-fluorouracil. Cancer Res. 54:632–636. 1994.PubMed/NCBI
7	Bhat KP, Itahana K, Jin A and Zhang Y: Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 23:2402–2412. 2004. View Article : Google Scholar : PubMed/NCBI
8	Dai MS, Zeng SX, Jin Y, Sun XX, David L and Lu H: Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol. 24:7654–7668. 2004. View Article : Google Scholar : PubMed/NCBI
9	Dai MS and Lu H: Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem. 279:44475–44482. 2004. View Article : Google Scholar : PubMed/NCBI
10	Dai MS, Shi D, Jin Y, Sun XX, Zhang Y, Grossman SR and Lu H: Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J Biol Chem. 281:24304–24313. 2006. View Article : Google Scholar : PubMed/NCBI
11	Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M and Vousden KH: Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell. 3:577–587. 2003. View Article : Google Scholar : PubMed/NCBI
12	Jin A, Itahana K, O'Keefe K and Zhang Y: Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol. 24:7669–7680. 2004. View Article : Google Scholar : PubMed/NCBI
13	Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA and Xiong Y: Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol. 23:8902–8912. 2003. View Article : Google Scholar : PubMed/NCBI
14	Sun XX, Dai MS and Lu H: 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J Biol Chem. 282:8052–8059. 2007. View Article : Google Scholar : PubMed/NCBI
15	Levine AJ and Oren M: The first 30 years of p53: Growing ever more complex. Nat Rev Cancer. 9:749–758. 2009. View Article : Google Scholar : PubMed/NCBI
16	Nabeya Y, Loganzo F Jr, Maslak P, Lai L, de Oliveira AR, Schwartz GK, Blundell ML, Altorki NK, Kelsen DP and Albino AP: The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer. 64:37–46. 1995. View Article : Google Scholar : PubMed/NCBI
17	Pickard M, Dive C and Kinsella AR: Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis. Br J Cancer. 72:1389–1396. 1995. View Article : Google Scholar : PubMed/NCBI
18	Osaki M, Tatebe S, Goto A, Hayashi H, Oshimura M and Ito H: 5-Fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: Role of the p53 gene. Apoptosis. 2:221–226. 1997. View Article : Google Scholar : PubMed/NCBI
19	Wright NA, Poulsom R, Stamp G, Van Noorden S, Sarraf C, Elia G, Ahnen D, Jeffery R, Longcroft J, Pike C, et al: Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology. 104:12–20. 1993. View Article : Google Scholar : PubMed/NCBI
20	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
21	Hong CF, Lin SY, Chou YT and Wu CW: MicroRNA-7 compromises p53 Protein-dependent apoptosis by controlling the expression of the chromatin remodeling factor SMARCD1. J Biol Chem. 291:1877–1889. 2016. View Article : Google Scholar : PubMed/NCBI
22	Yang Y, Nakagawa H, Tetreault MP, Billig J, Victor N, Goyal A, Sepulveda AR and Katz JP: Loss of transcription factor KLF5 in the context of p53 ablation drives invasive progression of human squamous cell cancer. Cancer Res. 71:6475–6484. 2011. View Article : Google Scholar : PubMed/NCBI
23	Petak I, Tillman DM and Houghton JA: p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines. Clin Cancer Res. 6:4432–4441. 2000.PubMed/NCBI
24	Adamsen BL, Kravik KL and De Angelis PM: DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status. Int J Oncol. 39:673–682. 2011.PubMed/NCBI
25	Dai MS, Arnold H, Sun XX, Sears R and Lu H: Inhibition of c-Myc activity by ribosomal protein L11. EMBO J. 26:3332–3345. 2007. View Article : Google Scholar : PubMed/NCBI
26	Boon K, Caron HN, Van Asperen R, Valentijn L, Hermus MC, Van Sluis P, Roobeek I, Weis I, Voûte PA, Schwab M, et al: N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 20:1383–1393. 2001. View Article : Google Scholar : PubMed/NCBI
27	Wang C, Li X, Zhang J, Ge Z, Chen H and Hu J: EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression. Onco Targets Ther. 11:7853–7864. 2018. View Article : Google Scholar : PubMed/NCBI
28	Xu X, Xiong X and Sun Y: The role of ribosomal proteins in the regulation of cell proliferation, tumorigenesis, and genomic integrity. Sci China Life Sci. 59:656–672. 2016. View Article : Google Scholar : PubMed/NCBI
29	Ajani JA: Evolving chemotherapy for advanced gastric cancer. Oncologist. 10:49–58. 2005. View Article : Google Scholar : PubMed/NCBI
30	Zhe W, Feng ZJ and Fang FG: Effect of rhizoma curcumate zedoariae and herbra trifolii repentis on apoptosis of human lung cancer cell line A549. J Capital Univ Med Sci. 22:304–305. 2001.
31	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI